Extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still); Extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still); Extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still); Skin rash in areas where skin contacts skin.; Begins with a burning red spot, appears to blister but doesn't; Begins with a burning red spot, appears to blister but doesn't; Itching follows/ Itching on both temple sides/ Scalp on sides of head itches severely in early mornings; skin turns almost shiny and rough; skin turns almost shiny and rough; Scalp has one spot that has crusted over but does not itch.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 20Apr2021 09:30 (Lot number: EW0170) at the age of 68 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: MONTELUKAST. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE, Lot Number : EP7533, Anatomical location: Left arm, Administration time: 09:30, Manufacturer unknown), administration date: 29Mar2021, when the patient was 67 years old, for COVID-19 immunisation; Varicella zoster vaccine, for immunisation, reaction(s): "No adverse effect"; Varicella zoster vaccine (Known allergies: No. Reacted #1 Shingles shot, shaking, no chills 4 hrs around 10 pm.), for immunisation, reaction(s): "Shaking". The following information was reported: FATIGUE (non-serious), HYPERSOMNIA (non-serious), PSYCHOMOTOR HYPERACTIVITY (non-serious) all with onset 20May2021, outcome "not recovered" and all described as "Extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still)"; RASH (non-serious) with onset 20May2021, outcome "not recovered", described as "Skin rash in areas where skin contacts skin."; SKIN BURNING SENSATION (non-serious), ERYTHEMA (non-serious) all with onset 20May2021, outcome "not recovered" and all described as "Begins with a burning red spot, appears to blister but doesn't"; PRURITUS (non-serious) with onset 20May2021, outcome "not recovered", described as "Itching follows/ Itching on both temple sides/ Scalp on sides of head itches severely in early mornings"; SKIN DISORDER (non-serious), DRY SKIN (non-serious) all with onset 20May2021, outcome "not recovered" and all described as "skin turns almost shiny and rough"; SCAB (non-serious) with onset 20May2021, outcome "not recovered", described as "Scalp has one spot that has crusted over but does not itch.". The events "extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still)", "extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still)", "extreme fatigue (can sleep 10 hour a day, very unusual high active nature, can't sit still)", "skin rash in areas where skin contacts skin.", "begins with a burning red spot, appears to blister but doesn't", "begins with a burning red spot, appears to blister but doesn't", "itching follows/ itching on both temple sides/ scalp on sides of head itches severely in early mornings", "skin turns almost shiny and rough", "skin turns almost shiny and rough" and "scalp has one spot that has crusted over but does not itch." were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of fatigue, hypersomnia, psychomotor hyperactivity. Therapeutic measures were taken as a result of rash, skin burning sensation, erythema, pruritus, skin disorder, dry skin, scab.  Additional Information: Concomitant medication included over counter antihistamine. The skin turned almost shiny and rough in nature where burning red spot began. Behind ears, in crevice of ear folds, behind knees, in crease of elbow, armpits, inside and around naval, waist area, place where top of legs contact body. The skin events were controlled with Mometasone Furoate Cream USP, 0.1% where possible. The patient did not receive any other vaccines within four weeks prior to COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.